Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas

British Journal of Cancer

Volumn 81, Issue 5, 1999, Pages 860-869

  Soubeyran, P ^a   Hostein, I ^a   Debled, M ^a   Eghbali, H ^a   Soubeyran, I ^a   Bonichon, F ^a   Astier Gin, T ^b   Hoerni B ^a  

^a INSTITUT BERGONIÉ   (France)

^b INSERM   (France)

Author keywords

bcl 2; Chemotherapy; Non hodgkin's lymphoma; Residual disease; t(14; 18)

Indexed keywords

CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; MONOCLONAL ANTIBODY; PREDNIMUSTINE; PREDNISONE; PROTEIN BCL 2; RNA; TENIPOSIDE; VINCRISTINE;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION FUNCTION; DOWN REGULATION; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; HYBRID GENE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM CIRCULATING CELLS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, NEOPLASM; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC;

EID: 0032720341     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690777     Document Type: Article

References (46)

1. Alnemri ES, Fernandes TF, Haldar S, Croec CM and Litwack G (1992) Involvement of BCL 2 in glucocorticoid-induced apoptosis of human pre B-leukemias. Cancer 52: 491-495
2. Aster JC, Kobayashi Y, Shiota M, Mori S and Sklar J (1992) Detection of the t(14;18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients. Am J Pathol 141: 291-299
3. Bell DA, Lin Y and Cortopassi GA (1995) Occurence of bel-2 oncogene translocalion with increased frequency in the peripheral blood of heavy smokers. J Natl Cancer Inst 87: 223-224
4. Bierman PJ, Vose JM, Anderson JR, Bishup MR, Kessinger A and Armitage JO (1997) High dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15: 445-450
5. Bonadonna G, Viviani S, Valagussa P, Bonfante V and Santoro A (1985) Third line salvage chemotherapy in Hodgkin's disease. Semin Oncol 12 (suppl 2): 23-25
6. Chauvergne J, Durand M, Hoerni B, Hoerni-Simon G, Brunet R and Lagarde C (1977) Induction chemotherapy of non-Hodgkin's malignant lymphomas. Preliminary results of a controlled trial. Eur J Cancer 13: 199-100
7. Cleary ML, Smith SD and Sklar J (1986) Cloning and structural analysis of cDNAs for bel-2 and a hybrid bel-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47: 19-28
8. Corbally N, Grogan L, Keane MM, Devaney DM, Dervan PA and Carney DN (1994) Bel-2 rearrangement in Hodgkin's disease and reactive lymph nodes. Am J Clin Pathol 101: 756-760
9. Dolken G, Illerhaus G, Hirt C and Mertelsmann R (1996) BCL-2/J(H) rearrangements in circulating B cells of healthy blood donors and patients with non-malignant diseases. J Clin Oncol 14: 1333-1344
10. Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ, Kroon M, Ritz J and Nadler LM (1996) High-dose therapy and analogous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88: 2780-2786
11. Fuscoe JC, Setzer RW, Collard DD and Moore MM (1996) Quantification of t(14;18) in the lymphocytes of healthy adult humans as a possible biomarker for environmental exposures to carcinogens. Carcinogenesis 17; 1013-1020
12. Gribben JC (1994) Attainment of molecular remission: a worthwhile goal? J Clin Oncol 12: 1532-1534
13. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J and Nadler LM (1991) Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325: 1525-1533
14. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E and Warnke RA (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84: 1361-1392
15. Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ (1990) Bel-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336
16. Ji WZ, Qu GZ, Ye P, Zhang XY, Halabi S and Ehrlich M (1995) Frequent detection of bel 2/J(H) translocations in human blood and organ samples by a quantitative polymerase chain reaction assay. Cancer Res 55: 2876-2882
17. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y and Cossman J (1993) Bel-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 5.1: 4251-4256
18. Keith FJ, Bradbury DA, Zhu YM and Russell NH (1995) Inhibition of bel-2 with anlisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara C. Leukemia 9: 131-138
19. Kitada S, Takayama S, De Riel K, Tanaka S and Reed JC (1994) Reversal of Lhcnioresislaiice of lymphoma cells by antisense-mediated reduction of bel-2 gene expression. Antisence Res Dev 4: 71-79
20. Kwok S and Higuchi R (1989) Avoiding false positive with PCR, Nature 339: 217-238
21. Lennert K and Feller AC (1992) Histopathology of non-Hodgkin's lymphomas. Springer Vrerlag: Berlin
22. Limpens J, de Jong D, van Krieken JH, Price CG, Young RD, van Ommeu GJ and Kluin PM (1991) Bel-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene 6: 2271-2276
23. Limpens J, Stad R, Vos C, de Vlaam C, de Jong D, van Ommen GJ, Schuuring E and Kluin PM (1995) Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 85: 2528-2536
24. Linette GP, Li Y, Roth K and Korsmeyer SJ (1996) Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation inaugural paper. Proc Natl Acad Sci USA 93: 9545-9552
25. Liu Y, Hernandez AM, Shibata D and Cortopassi GA (1994) BCL2 translocation frequency rises with age in humans. Proc Natl Sci USA 91: 8910-8914
26. Lotem J, Sachs L (1993) Regulation by bel 2, e-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective mycloid leukemic cells. Cell Growth Differ 4: 41-47
27. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M and Cabanillas F (1996) Fludarabine, mitoxantrone, and dexamethasone; An effective new regimen for indolent lymphoma. J Clin Oncol 14: 1262-1268
28. Mazel S, Burtrum D and Petrie HT (1996) Regulation of cell division cycle progression by bel-2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med 183: 2219-2226
29. Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment, Cancer 47: 207-214
30. Miyashita T and Reed JC (1992) Bel-2 gene transfer increases relative resistance of S49,1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52: 5407-5411
31. Miyashita T and Reed JC (1993) Bel-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157
32. O'Reilly LA, Huang DCS and Strasser A (1096) The cell death inhibitor Bel-2 and its homologues influence control of cell cycle entry. EMBO J 15: 6979-6990
33. Ohshima K, Kikuchi M, Kobari S, Masuda Y, Eguchi F and Kimura N (1993) Amplified bel-2/JH rearrangement in reactive lymphadenopathy. Virchows Arch B Cell Pathol Incl Mol Pathol 63: 197-198
34. Price CG, Tuszynski A, Watt SM, Murdoch SJ, Lister TA and Young BD (1991) Detection of additional JH/BCL2 translocations in follicular lymphoma. Leukemia 5: 548-554
35. Ravetch JV, Siebenlist U, Korsmeyer S, Waldmann T and Leder P (1981) Structure of the human immunoglobulin locus; characterization of embryonic and rearranged J and D genes. Cell 27: 583-591
36. Reed JC, Kitada S, Takayama S and Miyashita T (1994) Regulation of chemoresistance by the bel-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5 (suppl 1): S61-S65
37. Riehaud PM, Souheyran P, Eghbali H, Chacon B, Marit G, Broustet A and Hœrni B (1998) Place of low-dose total body irradiation in the treatment of localised follicular non Hodgkin's lymphoma: Results of a pilot study. Int J Radiat Oncol Biol Phys 40: 387-390
38. Rohatiner AZ, Johnson PW, Price CG, Arnott SJ, Amess JA, Norton AJ, Dorey E, Adams K, Whelan JS, Mathews J, MacCallum PK, Oza AM and Lister TA (1994) Myeloablative therapy with auotolognus bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12: 1177-1184
39. Sambrook J, Fritsch EF and Maniatis T (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor
40. Solal Celigny P, Lepage E, Brousse N, Reyes F, Haloun C, Leporrier M, Peuchmaun M, Bosly A, Parlier Y, Brice P, Coiffier B and Gisselbrecht C (1993) Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Emde des Lymphomes de l'Adulte. N Engl J Mol 329: 1608-1614
41. Soubeyran P, Eghbali H, Bonichon F, Coindre JM, Richaud P and Hœrni B (1988) Localized follicular lymphomas: prognosis and survival of stages I and II in a retrospective series of 103 patients. Radiother Oncol 13: 91-98
42. Soubeyran P, Eghbali H, Bonichon F, Trojani M, Richaud P and Hœrni B (1991) Low-grade follicular lymphomas; analysis of prognosis in a series of 281 patients. Eur J Cancer 27: 1606-1613
43. Soubeyran P, Cabanillas F and Lee MS (1993) Analysis of the expression of the hybrid gene bel 2/IgH in follicular lymphomas. Blood 81: 122-127
44. Tsujimoto Y, Croce CM (1986) Analysis of the structure, transcripts, and protein products ob bel-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214-5218
45. Vairo G, Innes KM and Adams JM (1996) Bel-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 13: 1511-1519
46. Weiss LM, Warnke RA, Sklar J and Cleary ML (1987) Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 317: 1185-1189